Bedaquiline as a potential agent in the treatment of M. intracellulare and M. avium infections Source: Eur Respir J , 49 (3) 1601969; DOI: 10.1183/13993003.01969-2016 Year: 2017
Is delamanid a potential agent in the treatment of diseases caused by Mycobacterium avium-intracellulare? Source: Eur Respir J 2016; 48: 1803-1804 Year: 2016
Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients Source: Eur Respir J 2013; 41: 1101-1106 Year: 2013
Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments Source: Eur Respir Rev, 31 (163) 210212; 10.1183/16000617.0212-2021 Year: 2022
Importance of identifying Mycobacterium bovis as a causative agent of human tuberculosis Source: Eur Respir J 2010; 35: 692-694 Year: 2010
Mycobacterium tuberculosis resistance Source: Eur Respir J 2002; 20: Suppl. 38, 360s Year: 2002
Pulmonary diseases caused by non-tuberculous mycobacteria Source: Eur Respir Mon 2012; 58: 25-37 Year: 2012
Amikacin exposure and susceptibility of macrolide-resistant Mycobacterium abscessus Source: ERJ Open Res, 5 (2) 00154-2018; 10.1183/23120541.00154-2018 Year: 2019
The spectrum of drug susceptibility of slow-growing nontuberculous mycobacteria (MAC, M. kansasii, M. xenopi) Source: International Congress 2017 – Clinical challenges in chronic lung diseases Year: 2017
Mycobacterium abscessus respiratory infection: importance in immunosuppressed patientsSource: Annual Congress 2008 - Lung and bone marrow transplantation: miscellaneous Year: 2008
Mycobacterium abscessus activates cross-resistance following antibiotic exposure Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020
Clinical relevance of Mycobacterium malmoense isolation in the Netherlands Source: Eur Respir J 2009; 34: 926-931 Year: 2009
Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis Source: Eur Respir J 2015; 46: 444-455 Year: 2015
Clinical and laboratory features of Mycobacterium avium complex infection in comparison with infection, caused by Mycobacterium tuberculosis, in HIV-infected patients Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019
Invasive Mycobacterium avium intracellulare infection Source: Eur Respir J 2006; 28: Suppl. 50, 312s Year: 2006
In vitro susceptibility testing of bedaquiline against mycobacteria avium-intracellulare complex Source: Virtual Congress 2020 – Aspergillosis and chronic lung infections Year: 2020
Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease Source: Eur Respir J, 54 (1) 1900118; 10.1183/13993003.00118-2019 Year: 2019
In vitro susceptibility of mycobacterium bovis against moxifloxacin Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011
Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease Source: Eur Respir J 2009; 33: 148-152 Year: 2009
Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020